Anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) agents are associated with the risk of adrenal insufficiency and hypophysis, whereas anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) therapy is closely associated with insulin-dependent DM and thyroid dysfunction. Here, CTLA4 is linked to hypophysitis.